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Controversy surrounds setting a lower limit of
normal testosterone. There is also no generally
accepted lower limits of normal testosterone level in
aging males. It was demonstrated that demographic
differences in testosterone level within population of
aging male exist (1ñ3). Testosterone bound to sex-
hormone binding protein (SHBG) is tightly bound
and thus biologically inactive. Bioavailable and free
testosterone is known to correlate better than total
testosterone with bone mineral density and muscle
strength, but it is difficult to calculate a bioavailable
testosterone level for all patients (4). Difficulties can
be found when one would classify the clinical syn-
drome related to late onset hypogonadism. It is due
to the high prevalence of hypogonadal symptoms in
the aging male population and the non-specific
nature of these symptoms. Late onset hypogonadism
often coexists with obesity and metabolic syndrome
(5, 6). The overall prevalence of late onset hypogo-
nadism varies from 6ñ9% in men aged 40ñ70 year
old and rises to 15ñ30% in diabetic and obese men
(7, 8). The management of late onset hypogonadism
is a testosterone supplementation. Therapy is usual-
ly scheduled for a period of a few months or a few
years. The population of men who can be potential-
ly treated with testosterone supplementation is
growing, due to many factors, like life longevity,
patients self-education, commercials and active drug
market and finally doctors decisions. The risk of
testosterone treatment is still not fully recognized. 
The aim of this mini review is to present a risk
of carcinogenesis within the prostate related to
testosterone treatment. 
Hormonal supplementation in elderly, what can
be learned from past studies? 
There is still considerable controversy con-
cerning influence of testosterone replacement on
the prostate gland, because incidence of BPH and
occult prostate cancer (PCa) in elderly are both high
(9). It is very interesting to compare the effects of
hormone replacement therapy in women and men
published in 2009. Evidences related to hormone
replacement therapy in men look very optimistic.
Testosterone, for example, has a wide range of ben-
eficial effects on menís health. It was suggested that
androgen deficiency is a risk factor for cardiovas-
cular disease (10). None of 44 controlled trials
demonstrated that testosterone therapy for hypogo-
nadism increased prostate cancer risk nor increased
tumor aggressiveness (Gleason grade) (11). It has
even been advocated that, under a rigorous surveil-
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lance, patients cured of prostate cancer can be treat-
ed with testosterone (12). On the other hand, scien-
tific data concerning hormone replacement therapy
in women are rather sceptic. The first placebo-con-
trolled trial of hormone therapy with the size and
statistical power, did not confirm the hormone-
healthy heart hypothesis in women (13). The inci-
dence of invasive breast cancer declined in the
United States following a nationwide decrease in
the use of hormone replacement therapy (14).
Regardless of the duration of use, the formulation,
estrogen dose, regimen, progestin type, and route of
administration, hormone therapy was associated
with an increased risk of ovarian cancer (15). Why
there are so huge differences between results of
hormone replacement therapy in women and men?
The answer probably could be found if the number
of published papers on which these two topics were
compared. It can be concluded that there are five
times as much papers on hormone replacement ther-
apy in women. There are 20,514 papers on hormone
replacement therapy women indexed in PubMed,
and 5,300 on hormone therapy women and cancer,
and 4,132 on hormone treatment and cardiovascular
diseases. On the other hand, there are only 5,459
papers on hormone replacement therapy in men and
only 950 papers related to cancer and hormone
replacement therapy in men, and only 890 analyz-
ing hormone therapy and cardiovascular diseases in
men. It can be hypothesized that data relating to
hormone replacement therapy in ageing males are
scanty. It is difficult to advise a safety long term
testosterone therapy for aging males, having in
mind that so many papers and long time observation
were devoted to hormone replacement therapy in
women and the results are still not satisfactory.
Testosterone influences on human prostate
The most interested issue is how testosterone
influences on both, epithelial and stromal cell com-
partments within the prostate? Testosterone is pre-
scribed as a drug which has no influence on lower
urinary tract symptoms in men. Does testosterone
really not influence on lower urinary tract symptoms
in elderly nor men suffering from BPH? To obtain
the correct answer one should rather ask; is a human
prostate sensitive on testosterone level manipulation
or not? Clinical trials have shown that testosterone
treatment of hypogonadal men cause growth of the
prostate, and increase in PSA within the normal
range (16). On the other hand, it was demonstrated
that finasteride (inhibitor of dihydrotestosterone,
DHT) induces prostate shrinkage, as well as
improvement of symptoms in men with BPH.
Discontinuation of this therapy induces prostate re-
growth, as well as aggravation of obstructive and
irritative symptoms generated within lower urinary
tract (17). It can be stated that androgens regulate
the proliferation of prostate cells within the gland
affected with benign prostatic hyperplasia (BPH).
Even in a small (44 patients) and short (6 months of
treatment) randomized controlled trial it was shown
that testosterone treatment had an effect on prostate
tissue androgen levels and cellular functions (18).
Androgens provide the signal for cell division in
normal and enlarged human prostate, as well. A ran-
domized, placebo-controlled trial of finasteride
treatment in 18,800 men showed a lower incidence
of prostate cancer in the treated group but increased
aggressive phenotype of detected cancers (19).
Based on these information, it can be stated that our
knowledge on carcinogenesis within the human
prostate is still obscure. We do not know, if testos-
terone could trigger cancer or recruit existing malig-
nant lesions to quicker growth or both. It has to be
emphasized that androgen receptor expression is
higher in cancer when compared to BPH tissue.
Prostate cancer is sensitive to testosterone (20). The
carcinogenesis within the prostate is a very long
process. Relationship between prevalence of
prostate cancer and age, support the fact that histo-
logical (occult) prostate cancer requires further
events to produce clinical disease. The incidence of
prostate cancer is rising among elderly. Autopsy
studies suggest that prostate cancer may be found in
80% of males over the age of 80 (21). Prostate car-
cinogenesis takes about 15 to 20 years, but most of
trials on testosterone replacement therapy and
prostate cancer are designed for duration of 3ñ5
years, so it is difficult to catch important finding
from these studies (11, 18). It is not surprising that
controversies on prostate carcinogenesis and testos-
terone replacement therapy in ageing males still
exist. It is not known, if histological (occult)
prostate cancer has already undergone or will have
to undergo events necessary to be converted into
clinical cancer? In other words, it is not known,
which of histological (occult) prostate cancers will
be converted to clinical one. It is not known, if an
epigenetic factor is needed to evoke carcinogenesis.
It is not known, how testosterone influences on car-
cinogenesis in man 40ñ50 year old, and what effect
could be expected after 10 or 20 years following
testosterone exposition. The knowledge on testos-
terone influence and de novo carcinogenesis within
the human prostate and possible ways of conver-
sions of malignant, occult lesions to clinical cancers
is obscure. 
Testosterone supplementation and prostate cancer, controversies still exist 545
Cell senescence, testosterone, and risk of prostate
cancer
Androgen replacement therapy in hypogonadal
men increases bone density, lean mass, enhances
heart muscle, cardiovascular function, and increased
prostate volume (17). Many beneficial effects of
testosterone therapy in aging males can be observed,
so why testosterone therapy is potentially danger in
aging male? This phenomenon can be explained
based on the function of P53 gene and P53 protein.
Active P53 stops cell division to repair DNA
defects. P53 helps to maintain genome stability and
prevents carcinogenesis. P53 is a tumor suppression
gene. It is inactive in young cells (progenitor cells),
because these cells are characterized by a low num-
ber of mutations and consequently, no danger of
carcinogenesis is present within them. Young cells
have high mitotic rate and young organisms have
high regenerative potential. On the other hand, P53
is active in older cells (differentiated cells) due to a
high number of mutations and risk of carcinogene-
sis. These cells present low mitotic rate connected
with the extensive DNA reparation processes. Aging
organism is characterized by low regenerative
potential and high risk of carcinogenesis (22ñ24).
Testosterone accelerates mitosis of senescent cells
containing DNA defects, which results in a lack of
DNA repair. It has to be emphasized that some con-
traindications for testosterone treatment are tumors
and proliferative disorders, like prostate cancer,
breast cancer, primary liver tumors, and poly-
cythemia (1). The reason for such contraindications
is because testosterone is an anabolic hormone, so it
has a mitogenic effect on cells. This fact increases a
risk of carcinogenesis within the prostate. Presented
mechanism is only a potential mechanism responsi-
ble for negative influence on the prostate.
Testosterone deficiency is an age related phenome-
non. Senescence increases risk of malignant disor-
ders. Our knowledge about the rules of machinery
contributing in human senescence is limited. We are
able only to describe phenomena occurred during
human aging and present them as theories. If
Richard Dawkins is right that ìwe are survival
machines blindly programmed to preserve genesî
than we may be convinced that our organisms are
planned to act properly during the period reserved
for reproduction, but not during the time of elderly
(25). It can be speculated that late onset hypogo-
nadism has to be regarded as a natural mechanism,
which protects heredity of defective traits. Late
onset hypogonadism is an immanent part of elderly
men.
CONCLUSIONS
Both epithelial and stromal cells within the
prostate are sensitive for manipulations of testos-
terone level. Senescence and high mitotic activity
increase the risk of cancer. It seems that testosterone
increases the risk of prostate cancer and aggravation
of lower urinary tract symptoms in BPH patients,
but trials dedicated to these relations are too short
and recorded data are still scanty.
We hypothesized that there is too early to state
that testosterone treatment is a risk free management
of late-onset hypogonadism in men. 
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